Literature DB >> 14576989

Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.

P Oelzner1, B Deliyska, R Fünfstück, G Hein, D Herrmann, G Stein.   

Abstract

The aim of this study was to investigate the relationship between the presence and titre of antibodies against C1q (anti-C1q Ab) and disease activity and renal involvement in patients with systemic lupus erythematosus (SLE). Anti-C1q Ab were measured in 79 patients with SLE (70 women and 9 men; mean age 41.7 years; mean disease duration 8.4 years): 19 patients had active disease with lupus nephritis, 8 active disease without nephritis, 26 inactive disease with nephritis and 26 inactive disease without nephritis. Anti-dsDNA antibodies (EIA and immunofluorescence), antiendothelial cell antibodies (AECA) and complement levels (C3, C4, total haemolytic complement activity) were determined in parallel. Anti-C1q Ab were positive in 49%, anti-dsDNA Ab in 61% and AECA in 19% of the patients, respectively. Significantly higher titres of anti-C1q Ab were found in patients with active disease compared with those with inactive SLE ( P < 0.01). Serum levels of anti-C1q Ab showed a positive correlation with anti-dsDNA Ab and SLEDAI score ( P < 0.01) and a negative correlation with C3 ( P < 0.05), C4 ( P < 0.01) and CH50U ( P < 0.01). The presence of anti-C1q Ab was not different between patients with or without nephritis. In patients with ( P < 0.05) and without nephritis ( P < 0.01) the frequency of anti-C1q Ab was significantly higher in active patients compared with inactive patients. Both anti-C1q and anti-ds-DNA Ab were detectable in 74% of patients with active nephritis but only in 30% of all other patients ( P=0.001). None of the patients with active nephritis was negative for anti-C1q and anti-dsDNA Ab, whereas 37% of the patients without active nephritis were negative for both antibodies ( P < 0.01). Sensitivity, specificity, positive and negative predictive values for active lupus nephritis among SLE patients were 100%, 50%, 51.9% and 100% for anti-dsDNA Ab (EIA) and 74%, 70%, 57% and 89.4% for positive findings of both anti-dsDNA and anti-C1q Ab. The presence and titre of anti-C1q-Ab in SLE are related to disease activity. Absence of anti-dsDNA Ab excludes active nephritis; positive findings of both anti-dsDNA Ab and anti-C1q Ab are of relatively high specificity for active nephritis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576989     DOI: 10.1007/s10067-003-0724-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China.

Authors:  Cai-Qin Zhang; Lei Ren; Fei Gao; Feng-Yun Mu; Yan-Qiu You; Yan-Hong Liu
Journal:  Clin Rheumatol       Date:  2011-02-23       Impact factor: 2.980

2.  Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.

Authors:  Heikki Julkunen; Susanne Ekblom-Kullberg; Aaro Miettinen
Journal:  Rheumatol Int       Date:  2011-06-26       Impact factor: 2.631

3.  Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus.

Authors:  M Pejchinovski; J Siwy; W Mullen; H Mischak; M A Petri; L C Burkly; R Wei
Journal:  Lupus       Date:  2017-05-05       Impact factor: 2.911

4.  Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels.

Authors:  Hiroyuki Wakiguchi; Syuji Takei; Tomohiro Kubota; Akinori Miyazono; Yoshifumi Kawano
Journal:  Clin Rheumatol       Date:  2016-11-30       Impact factor: 2.980

5.  Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity.

Authors:  Sladjana Andrejevic; Ivica Jeremic; Mirjana Sefik-Bukilica; Milos Nikolic; Biljana Stojimirovic; Branka Bonaci-Nikolic
Journal:  Clin Rheumatol       Date:  2013-07-16       Impact factor: 2.980

6.  C1q complement component and -antibodies reflect SLE activity and kidney involvement.

Authors:  P Horák; Z Hermanová; J Zadrazil; H Ciferská; M Ordeltová; L Kusá; M Zurek; T Tichý
Journal:  Clin Rheumatol       Date:  2005-11-26       Impact factor: 2.980

7.  Anti-C1q Antibody is Associated with Renal and Cutaneous Manifestations in Asian Indian Patients with Systemic Lupus Erythematosus.

Authors:  Jayakanthan Kabeerdoss; Nikhil Gupta; Sandhya Pulukool; Hindhumathi Mohan; Gowri Mahasampath; Debashish Danda
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis.

Authors:  Paola Margutti; Paola Matarrese; Fabrizio Conti; Tania Colasanti; Federica Delunardo; Antonella Capozzi; Tina Garofalo; Elisabetta Profumo; Rachele Riganò; Alessandra Siracusano; Cristiano Alessandri; Bruno Salvati; Guido Valesini; Walter Malorni; Maurizio Sorice; Elena Ortona
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

9.  Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus.

Authors:  Carlos Geraldo Moura; Isabella Lima; Lúcio Barbosa; Daniel Athanazio; Eliana Reis; Mitermayer Reis; Rufus W Burlingame; Mittermayer B Santiago
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

10.  Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus.

Authors:  Timothy Li; Stephenie D Prokopec; Stacey Morrison; Wendy Lou; Heather Reich; Dafna Gladman; Murray Urowitz; James Scholey; Paul R Fortin; Paul C Boutros; Joan Wither; Carolina Landolt-Marticorena
Journal:  Rheumatology (Oxford)       Date:  2014-09-05       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.